Italian Drugmaker Chiesi to Acquire KalVista for $1.9 Billion
Chiesi's $1.9B acquisition of KalVista signals a strategic expansion in rare immunology, with implications for rare disease treatment supply and commercialization.

UNIPHARMA INSIGHTS
Chiesi's $1.9B acquisition of KalVista signals a strategic expansion in rare immunology, with implications for rare disease treatment supply and commercialization.
A new integrated polygenic risk score tool for eight cardiovascular conditions enables early risk identification and may shift preventive cardiology workflows.
Precision immunotherapy for SLE targets specific immune pathways, shifting from broad immunosuppression to mechanism-based therapies. Implications for drug development and market access.
Chiesi Group acquires KalVista for $1.9B, gaining oral HAE drug EKTERLY, expanding US presence and targeting €6B revenue by 2030.
Chiesi’s $1.9bn acquisition of KalVista brings sebetralstat, the first oral on-demand therapy for hereditary angioedema, expanding its rare disease pipeline.
The aspirin market is set to reach $3.51B by 2030. Sun Pharma's acquisition of Taro and Bayer's digital health partnership reshape the competitive landscape for buyers and distributors.
Reference pages
A
Drug shortage supplier is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Early Access Medicine is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Unlicensed Medicines is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.